KPV

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is KPV?

KPV is the tripeptide sequence Lys-Pro-Val, corresponding to positions 11–13 of the alpha-MSH molecule. The name itself is simply the one-letter amino acid codes: K (lysine), P (proline), V (valine). This KPV tripeptide was first identified as a bioactive fragment when researchers studying alpha-MSH discovered that the anti-inflammatory properties of the full 13-amino-acid hormone could be preserved in much smaller fragments.[1][2]

The structural simplicity of KPV is part of its appeal in research. As a tripeptide, it is far smaller than alpha-MSH (which itself is only 1,665 Da), making synthesis straightforward and cost-effective. Unlike many larger peptides, the KPV peptide can be absorbed through epithelial barriers — a property that has driven particular interest in oral delivery for gastrointestinal applications.[4]

Alpha-MSH is produced in the pituitary gland, skin, gut, and immune cells, and signals primarily through melanocortin receptors (MC1R through MC5R). However, the KPV fragment does not appear to require melanocortin receptor binding for its anti-inflammatory effects — a critical distinction that separates it from compounds like Melanotan 2, which directly agonises melanocortin receptors to produce tanning and other effects.[1][7]

Compound Profile

Mechanism of Action

The central mechanism identified in KPV research is inhibition of nuclear factor kappa-B (NF-κB), the master transcription factor controlling inflammatory gene expression. This KPV anti inflammatory action operates through a pathway that appears independent of classical melanocortin receptor signalling.[1][4]

Key mechanistic findings from the literature:

• NF-κB translocation inhibition: KPV prevents the nuclear translocation of NF-κB subunits (p65/p50) in multiple cell types, including colonocytes, keratinocytes, and macrophages. This blocks upstream activation of inflammatory gene transcription.[4][7]
• Pro-inflammatory cytokine suppression: downstream of NF-κB inhibition, KPV reduces production of TNF-α, IL-1β, and IL-6 — the core inflammatory cytokines driving tissue damage in conditions like colitis and dermatitis.[1][3]
• PepT1-mediated cellular uptake: a landmark finding from the Dalmasso (2008) study demonstrated that KPV enters intestinal epithelial cells via PepT1, the peptide transporter responsible for absorbing dietary di- and tripeptides. Once internalised, KPV directly interacts with intracellular inflammatory signalling pathways.[4]
• Melanocortin-independent activity: unlike full-length alpha-MSH, KPV does not appear to require MC1R or other melanocortin receptor engagement for its anti-inflammatory effects. This has been demonstrated in cells lacking melanocortin receptors, where KPV still reduces inflammatory markers.[1][7]

The PepT1 uptake pathway is particularly noteworthy. PepT1 is expressed along the entire intestinal epithelium and is upregulated during intestinal inflammation, meaning KPV uptake may actually increase in precisely the conditions where its anti-inflammatory effects are most relevant.[4] This mechanism is distinct from how peptides like BPC-157 are thought to interact with the gut, though both are studied in gastrointestinal inflammation contexts.

Inflammatory Bowel Disease Research

The most developed research area for KPV is inflammatory bowel disease (IBD), encompassing both ulcerative colitis and Crohn’s disease models. The KPV gut research programme has produced some of the peptide’s most compelling preclinical data.[3][4]

Kannengiesser et al. (2008) tested KPV in two established murine colitis models: DSS (dextran sodium sulphate)-induced colitis and the TNBS (trinitrobenzene sulphonic acid) model. In both systems, KPV significantly reduced colonic inflammation as measured by clinical disease activity scores, histological damage, and myeloperoxidase activity (a marker of neutrophil infiltration). The effect was dose-dependent and comparable in magnitude to standard anti-inflammatory interventions used in these models.[3]

Dalmasso et al. (2008) published a complementary study in Gastroenterology (a top-tier journal in the field) demonstrating that KPV could be delivered orally and still exert anti-inflammatory effects in colitis models. The critical finding was the PepT1 uptake mechanism: KPV is absorbed directly into inflamed colonocytes through the same transporter that handles dietary peptides. Once inside cells, KPV inhibited NF-κB activation and reduced secretion of pro-inflammatory cytokines. The oral delivery finding is significant because it suggests KPV could potentially reach its target tissue (the inflamed intestinal lining) through a simple delivery route.[4]

A practical limitation: both studies used animal models of chemically induced colitis, which do not perfectly replicate human IBD. No human clinical trials investigating KPV for colitis or Crohn’s disease have been completed. The translation gap between murine colitis models and human IBD is historically large — many compounds that show strong effects in DSS colitis models fail to demonstrate equivalent benefit in human trials.

For comparison, BPC-157 has also been studied in similar colitis models with promising preclinical results. Like KPV, BPC-157 has not progressed through controlled human IBD trials, though its gastrointestinal research base is broader in scope.

Wound Healing & Dermatology Research

The KPV skin research area draws heavily on the broader alpha-MSH dermatology literature. Alpha-MSH and its fragments have been studied in various skin inflammation models, and the anti-inflammatory mechanism relevant to gut epithelium applies similarly to keratinocytes and dermal tissue.[1][8]

Key findings in the dermatology context:

• Keratinocyte inflammation: alpha-MSH-derived tripeptides, including KPV-related sequences, suppress IL-1β-mediated cytokine expression in skin cell models. The Mastrofrancesco (2010) study demonstrated this directly using KdPT (a closely related tripeptide) in human sebocytes, showing suppression of inflammatory signalling cascades relevant to acne and sebaceous gland inflammation.[9]
• Wound healing potential: Böhm and Luger (2019) reviewed the evidence for melanocortin peptides in cutaneous wound healing, noting that alpha-MSH fragments can promote keratinocyte migration, reduce wound-bed inflammation, and support organised tissue remodelling. However, most wound healing data involves the full alpha-MSH molecule rather than the KPV fragment specifically.[8]
• Contact dermatitis models: in mouse models of contact hypersensitivity (a model for allergic dermatitis), alpha-MSH and its fragments reduce ear swelling, inflammatory cell infiltration, and local cytokine production. KPV-range fragments have shown activity in these models.[1][7]

The honest assessment of KPV skin evidence: most published data uses either the full alpha-MSH molecule or closely related tripeptides (KdPT, KPV analogues), rather than KPV itself in isolation. The assumption that KPV’s activity transfers directly from alpha-MSH fragment research is reasonable based on structure-activity studies, but direct KPV-specific skin data remains limited. For peptides with stronger direct evidence in skin biology, the GHK-Cu profile covers a compound with more extensive topical research.

Antimicrobial Properties

An unexpected dimension of KPV research is its antimicrobial peptide activity. Cutuli et al. (2000) demonstrated that alpha-MSH peptides, including C-terminal fragments encompassing the KPV sequence, possess direct antimicrobial effects against both bacteria and fungi.[6]

The antimicrobial findings include:

• Anti-candidal activity: alpha-MSH fragments containing the KPV sequence showed candidacidal activity against Candida albicans in vitro. This effect was enhanced by modifying the peptide to a dimeric form (CKPV)₂, which showed greater potency than the monomeric sequence.[6]
• Antibacterial effects: modest bactericidal activity was observed against Staphylococcus aureus and Escherichia coli, though at higher concentrations than required for anti-candidal effects.[6]
• Dual mechanism hypothesis: the combined anti-inflammatory and antimicrobial properties of KPV-containing sequences have led researchers to propose a dual-function role — simultaneously reducing pathogen burden and dampening the inflammatory tissue damage that infections cause.[6][7]

This antimicrobial peptide activity positions KPV-related sequences in an interesting category alongside classical antimicrobial peptides (defensins, cathelicidins), though the potency is generally lower than dedicated antimicrobial compounds. The clinical relevance of KPV’s antimicrobial activity remains theoretical without human infection model data.

Side Effects & Safety Profile

Discussing KPV peptide side effects requires acknowledging a fundamental limitation: there are no completed human clinical trials with KPV. The safety profile is therefore extrapolated from animal studies, in vitro toxicity assessments, and the broader alpha-MSH safety literature.[1]

What can be reasonably stated:

• Animal model tolerability: in the murine colitis studies by Kannengiesser et al. (2008) and Dalmasso et al. (2008), KPV was administered systemically and orally without reported adverse effects at therapeutic doses. No weight loss, organ toxicity, or behavioural changes were noted.[3][4]
• Theoretical safety advantages: because KPV does not activate melanocortin receptors, it should not produce the pigmentation changes, nausea, facial flushing, or sexual arousal effects associated with melanocortin agonists like Melanotan 2 or PT-141.[1]
• Immunosuppression considerations: any compound that suppresses NF-κB and inflammatory cytokines carries a theoretical risk of impairing immune defence when used systemically. This is a class concern shared with established anti-inflammatory therapies, not specific to KPV.
• Peptide stability and purity: as a tripeptide, KPV is relatively simple to synthesise, but research-grade peptides may contain impurities that would not be present in pharmaceutical-grade products. Purity considerations apply to any research peptide.

The absence of human safety data is the dominant feature of the KPV side effects discussion. Preclinical tolerability does not guarantee human safety, and the dose-response relationship in humans has not been characterised.

Pharmacokinetics

KPV’s pharmacokinetic profile reflects both the advantages and limitations of tripeptide compounds:

• Half-life: short, as expected for a tripeptide. Small peptides are rapidly cleared by peptidases in plasma and tissues. Precise half-life values for KPV in circulation have not been extensively characterised in published literature, but tripeptides generally have half-lives measured in minutes rather than hours.
• Oral absorption: the PepT1-mediated uptake demonstrated by Dalmasso et al. (2008) is the most pharmacokinetically relevant finding. PepT1 is a high-capacity, low-affinity transporter for di- and tripeptides, meaning KPV can be absorbed across the intestinal epithelium through a natural transport mechanism. This is unusual for peptides — most require injection to bypass gastrointestinal degradation.[4]
• Local vs systemic effects: the PepT1 uptake pathway delivers KPV directly into epithelial cells rather than the systemic circulation. For gastrointestinal applications, this may actually be advantageous — the peptide reaches its target cells (inflamed colonocytes) without needing significant systemic exposure.
• Delivery routes under investigation: published research has used subcutaneous injection, intraperitoneal injection, and oral administration. The oral route is most studied for IBD applications, while injectable delivery has been used in systemic inflammation models.

The pharmacokinetic profile of KPV differs substantially from longer research peptides like TB-500 or BPC-157, which have longer half-lives and different distribution characteristics. KPV’s tripeptide size makes it more susceptible to enzymatic degradation but potentially more amenable to oral delivery.

FAQ

What is KPV peptide used for in research?

KPV peptide is primarily studied for its anti-inflammatory properties, with research focusing on inflammatory bowel disease (colitis models), skin inflammation and wound healing, and antimicrobial activity. All current evidence comes from in vitro and animal studies — KPV has not been tested in human clinical trials. Researchers investigate KPV because it retains the anti-inflammatory effects of its parent molecule alpha-MSH without causing pigmentation or other melanocortin receptor-mediated effects.

What are the potential KPV peptide benefits identified in research?

Published research has identified several potential KPV peptide benefits in preclinical models: reduction of intestinal inflammation in colitis models, suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), direct antimicrobial activity against bacteria and fungi, and modulation of skin inflammatory responses. These findings have not been confirmed in human studies, and the translation from animal models to human outcomes is uncertain.

How does KPV differ from alpha-MSH?

KPV is a three-amino-acid fragment (positions 11–13) of the 13-amino-acid alpha-MSH molecule. The critical difference is receptor specificity: alpha-MSH binds melanocortin receptors (MC1R–MC5R), producing pigmentation, appetite suppression, and sexual function effects. KPV does not bind these receptors, so it does not cause tanning or other receptor-mediated effects. KPV retains only the receptor-independent anti-inflammatory and antimicrobial properties of alpha-MSH.

Can KPV be taken orally?

Animal research has demonstrated that KPV can be absorbed orally through the PepT1 intestinal peptide transporter, which is significant because most peptides cannot survive gastrointestinal digestion. The Dalmasso (2008) study showed oral KPV reduced intestinal inflammation in colitis models. However, no human pharmacokinetic data exists to confirm oral bioavailability, optimal dosing, or efficacy in people.

What are the known KPV peptide side effects?

No human safety data exists for KPV. In animal studies, KPV was administered without reported adverse effects at experimental doses. Because KPV does not activate melanocortin receptors, it should not cause the nausea, flushing, or pigmentation changes associated with melanocortin agonists. Theoretical concerns include potential immunosuppression from NF-κB inhibition and standard peptide purity considerations.

Is KPV FDA approved?

No. KPV is not approved by the FDA or any regulatory agency for any medical indication. It is classified as a research compound. There are no active clinical trials registered for KPV in humans. Any use outside of research settings would be considered experimental and off-label.

How does KPV compare to BPC-157 for gut health research?

Both KPV and BPC-157 have been studied in gastrointestinal inflammation models, but they work through different mechanisms. KPV acts primarily through NF-κB inhibition and PepT1-mediated cellular uptake, while BPC-157 is thought to work through VEGF modulation, NO system interaction, and growth factor pathways. BPC-157 has a larger overall evidence base spanning more tissue types. Neither peptide has completed human clinical trials for IBD.

What is the evidence quality for KPV research?

The evidence quality for KPV is limited. The strongest data comes from two well-designed animal colitis studies (Kannengiesser 2008, Dalmasso 2008) published in respected journals. Antimicrobial and dermatology data is primarily in vitro. There are no randomised controlled human trials, no dose-finding studies in humans, and no long-term safety data. The research is promising but preliminary.

References

1. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581-602. PMID: 18612139
2. Luger TA, Scholzen TE, Brzoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Annals of the New York Academy of Sciences. 2003;994:133-140. PMID: 12851308
3. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. PMID: 18092346
4. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177
5. Getting SJ. Targeting melanocortin receptors as potential novel therapeutics. Pharmacology & Therapeutics. 2006;111(1):1-15. PMID: 16488018
6. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233-239. PMID: 10670585
7. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases. 2007;66(Suppl 3):iii52-55. PMID: 17934097
8. Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Dermatology. 2019;28(3):219-224. PMID: 30661264
9. Mastrofrancesco A, Kokot A, Eberle A, et al. KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1β-mediated cytokine expression and signaling in human sebocytes. Journal of Immunology. 2010;185(3):1903-1911. PMID: 20610647